# Picard Medical, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Picard Medical, Inc.). ## Overview Picard Medical, Inc. is a U.S.-based medical technology holding company whose operating business is conducted through SynCardia. The company develops, manufactures, and sells the SynCardia Total Artificial Heart, an FDA-approved implantable device used to temporarily replace both ventricles of the heart in patients with advanced heart failure. ## Products & services • SynCardia Total Artificial Heart (TAH) • External Freedom drivers for the TAH system • Training and certification for transplant centers • Patient aftercare support for implanted-device programs - **Implantable total artificial heart systems** (65%) — FDA-approved implantable heart replacement devices used as a bridge to transplant. - **Driver rentals** (20%) — Rental of external Freedom drivers that power the implanted heart system. - **Training and certification services** (10%) — Required training for transplant centers before first-time deployment of the system. - **Aftercare and related services** (5%) — Support services for centers and patients using the SynCardia platform. - SynCardia Total Artificial Heart (TAH) - External Freedom drivers for the TAH system - Training and certification for transplant centers - Patient aftercare support for implanted-device programs ## Customers Customers are specialized transplant centers and hospital programs that treat patients with advanced heart failure and need a bridge-to-transplant solution. The buying decision is driven by clinical need, regulatory approval, surgeon and center readiness, and the ability to support implantation, driver use, and patient management. The company also serves centers outside the U.S. where the device is available under special exemptions or compassionate use pathways. - **U.S. transplant centers** (primary) — Buy the implantable TAH, driver rentals, and training to treat bridge-to-transplant patients. - **International transplant centers** (secondary) — Use the system under special exemptions or compassionate use for selected patients. - **Hospital and clinical programs** (secondary) — Purchase support services and device-related infrastructure to run the therapy. - **Patient aftercare programs** (emerging) — Use ongoing support tied to implanted patients and center operations. - Heart transplant centers that implant the TAH - Hospitals treating advanced heart failure patients - Centers needing driver rentals and clinical support - Programs requiring training before first use - International centers using special-access pathways ## Geography The company is headquartered in the United States, where the SynCardia TAH is commercially approved and sold. It also has a global footprint through use in multiple countries under special exemptions or compassionate use, which broadens the addressable market but adds regulatory and access complexity. - United States is the core commercial market - Device is FDA-approved for U.S. bridge-to-transplant use - International use occurs under special exemptions - Implants have been reported in 27 countries globally - Foreign access depends on local regulatory pathways ## Strategy Picard Medical's strategy is centered on SynCardia and the next generation of total artificial heart technology. Management also describes a broader plan to build a cardiovascular medical technology portfolio through acquisition, development, or in-licensing of approved or near-approved assets. - **Develop next-generation total artificial heart systems** (medium-term) — Improves usability, outcomes, and long-term competitiveness of the platform. - **Expand the cardiovascular portfolio** (long-term) — Reduces dependence on a single product and broadens future growth options. - **Protect and extend intellectual property** (medium-term) — Patent protection supports differentiation and barriers to entry. - Advance successive generations of the SynCardia TAH - Improve clinical outcomes and patient quality of life - Expand the cardiovascular technology portfolio - Pursue acquisitions and in-licensing of assets - Protect the platform with patents and IP ## Risks The business is highly concentrated in a single commercial product and depends on a narrow set of specialized customers, so adoption, reimbursement, and clinical acceptance are important to growth. As a medical device company, it also faces regulatory, manufacturing, and product-liability risks, while international use depends on country-specific access pathways. The company has also disclosed reliance on external financing, which is common for early-stage medtech businesses with long development cycles. - **Product concentration** [high] — Most business activity depends on one FDA-approved heart system. - **Regulatory and reimbursement dependence** [high] — Sales depend on approval status, special exemptions, and hospital economics. - **Clinical adoption risk** [medium] — Transplant centers must be trained and willing to deploy a complex device. - **Manufacturing and quality risk** [high] — Implantable devices require consistent production quality and traceability. - **Financing and liquidity risk** [high] — The company has relied on external capital to fund operations and growth. - Single-product concentration in the SynCardia platform - Regulatory approval and access pathways can limit sales - Clinical adoption depends on transplant-center readiness - Manufacturing quality and supply continuity are critical - Financing needs may constrain operations and development ## Accounting Revenue is driven by a mix of product sales, rentals, and training/services, so timing can differ by transaction type and customer deployment cycle. Investors should also watch inventory valuation and obsolescence, embedded derivative accounting on convertible instruments, and stock-based compensation, all of which can materially affect reported results for a development-stage medtech company. - **Revenue recognition by product, rental, and services** — Affects quarterly comparability and reported revenue mix - **Inventory valuation and obsolescence** — Affects cost of revenues and gross loss - **Embedded derivatives in convertible instruments** — Affects earnings volatility - **Stock-based compensation and debt discount amortization** — Affects operating expenses and financing-related costs - Mixed revenue streams create different recognition timing - Driver rentals and services may be recognized over time - Inventory and obsolescence charges affect gross margin - Convertible notes can create embedded derivative volatility - Stock-based compensation and debt discounts affect expenses --- *Last updated: 2026-04-29T04:48:45.470142+00:00*